Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT03048474 | Ipilimumab and Nivolumab in the Treatment of Malignant Pleural Mesothelioma | PHASE2 | COMPLETED | 36 | — | — | Sep 1, 2016 | Dec 1, 2019 | Jan 20, 2021 | 1 | Netherlands |
The number of patients that have CR or PR plus the number of patients with stable disease as a percentage of the total number of patients in the study.
| Arm | Type | Description |
|---|---|---|
| Nivolumab and Ipilimumab | EXPERIMENTAL | Nivolumab will be administered at a fixed dose of 240 mg every 2 weeks for a maximum period of 2 years. Nivolumab will be given in combination with ipilimumab on week 1, 7, 13 and 19. Ipilimumab will be administered at the dose of 1 mg/Kg. |
| Name | Type | Description |
|---|---|---|
| nivolumab and ipilimumab | DRUG | - |
Inclusion Criteria: * Signed informed consent form * Age ≥ 18 years * WHO-ECOG performance status 0 or 1 * Able to comply with the study protocol, in the investigator's judgment * Patients with histologically confirmed diagnosis of the recurrence of MPM. Any pleural MPM subtype is permitted for inc...